{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:30:19Z","timestamp":1787855419158,"version":"build-2784847793"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canada's Drug Agency","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Both pharmaceutical and non-pharmaceutical opioids contribute to overdoses and other drug-related harms in Canada; however, the role of these sources of opioids have been dynamic over the past two decades and vary geographically. Therefore, we sought to examine trends in the prevalence of prescription opioid exposure at the time of opioid toxicity hospitalizations and emergency department (ED) visits across Canada over the past 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a population-based repeated cross-sectional study of yearly opioid toxicities treated in an inpatient hospital setting in 6 Canadian provinces\u2015British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Quebec\u2015between January 2018 and December 2022. We linked hospitalization records with community pharmacy dispensing data to determine active exposure to prescribed opioids at the time of opioid toxicity, annually and stratified by patient characteristics and type of opioid dispensed. In a secondary analysis, we replicated these methods among opioid toxicities treated in EDs in 5 provinces where data were available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 23,876 opioid toxicity hospital admissions over the study period. Active opioid exposure at the time of hospital admission declined across provinces over time, apart from British Columbia (range, 20.0% in British Columbia to 47.5% in Quebec in 2018; 19.7% in British Columbia to 36.5% in Quebec in 2022). Generally, people \u226565 and females were proportionally more likely to have an active opioid exposure. When stratified by opioid type, we observed a shift towards active exposure to opioid agonist treatment (OAT), while active exposure to opioids for pain declined over time. Active opioid exposure was less common at the time of opioid toxicity ED visit but was more stable over time (range, 11.0% in British Columbia to 28.5% in Quebec in 2018; 14.9% in Alberta to 26.0% in Quebec in 2022), with only small declines in most provinces (Alberta, Ontario, and Quebec), and an increase in British Columbia (from 11.0% in 2018 to 16.8% in 2022), which was driven by a large increase in active OAT exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight the increasing role of the potent unregulated drug supply in opioid toxicities across Canada, as well as important differences in the role of prescription opioids in harms across demographic groups, geography, and opioid indication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0339643","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:22:53Z","timestamp":1768242173000},"page":"e0339643","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Opioid dispensing prior to opioid toxicity hospitalizations and emergency department visits in Canada, 2018\u20132022"],"prefix":"10.1371","volume":"21","author":[{"given":"Bisola","family":"Hamzat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean T.","family":"Eurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Kabor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"de L\u00e9s\u00e9leuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssem","family":"Missaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Shearer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-1965","authenticated-orcid":true,"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"pone.0339643.ref001","volume-title":"Opioid- and stimulant-related harms in Canada","author":"Federal provincial and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2024"},{"key":"pone.0339643.ref002","unstructured":"National Institute of Drug Abuse. Drug overdose death rate. [Cited 2025 April 1]. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"},{"issue":"14","key":"pone.0339643.ref003","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.231339","article-title":"Opioid-related deaths between 2019 and 2021 across 9 Canadian provinces and territories","volume":"196","author":"S Ledlie","year":"2024","journal-title":"CMAJ"},{"key":"pone.0339643.ref004","unstructured":"Canada Mortgage and Housing Corporation. Real average before-tax household income quintiles by tenure, 2006 \u2013 2023. 2025. https:\/\/www.cmhc-schl.gc.ca\/professionals\/housing-markets-data-and-research\/housing-data\/data-tables\/household-characteristics\/real-average-before-tax-household-income-quintiles"},{"key":"pone.0339643.ref005","doi-asserted-by":"crossref","first-page":"100240","DOI":"10.1016\/j.dadr.2024.100240","article-title":"Fentanyl, carfentanil and other fentanyl analogues in Canada\u2019s illicit opioid supply: A cross-sectional study","volume":"12","author":"RA Kleinman","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"key":"pone.0339643.ref006","article-title":"Trends in Opioid Prescribing in Canada, 2018\u201322","author":"T Gomes","year":"2025"},{"issue":"4","key":"pone.0339643.ref007","doi-asserted-by":"crossref","DOI":"10.9778\/cmajo.20170104","article-title":"Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis","volume":"5","author":"T Gomes","year":"2017","journal-title":"CMAJ Open"},{"issue":"36","key":"pone.0339643.ref008","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.250670","article-title":"Trends in prescription opioid use for pain in Canada: a population-based repeated cross-sectional study of 6 provinces","volume":"197","author":"N Rebi\u0107","year":"2025","journal-title":"CMAJ"},{"issue":"1","key":"pone.0339643.ref009","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12954-017-0177-7","article-title":"Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks","volume":"14","author":"E Hyshka","year":"2017","journal-title":"Harm Reduct J"},{"issue":"3","key":"pone.0339643.ref010","first-page":"49","article-title":"Methadone prescribing regulation for opioid use disorder in Canada: Evidence for an East-West Policy Divide","volume":"19","author":"C Campbell","year":"2024","journal-title":"Healthc Policy"},{"issue":"7","key":"pone.0339643.ref011","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0706743717711167","article-title":"The state of opioid agonist therapy in canada 20 years after federal oversight","volume":"62","author":"JK Eibl","year":"2017","journal-title":"Can J Psychiatry"},{"key":"pone.0339643.ref012","article-title":"Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada","volume":"362","author":"T Gomes","year":"2018","journal-title":"BMJ"},{"issue":"8","key":"pone.0339643.ref013","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"E von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"pone.0339643.ref014","unstructured":"Gouvernement du Qu\u00e9bec, R\u00e9gie de l\u2019assurance maladie. 2020. [Cited 2025 March 28]. https:\/\/www.ramq.gouv.qc.ca\/en"},{"key":"pone.0339643.ref015","article-title":"Trends in opioid prescribing and associated harms in Canada, 2018 to 2022: Study protocol","author":"T Gomes","year":"2025"},{"key":"pone.0339643.ref016","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.drugalcdep.2018.06.028","article-title":"Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study","volume":"191","author":"T Gomes","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"pone.0339643.ref017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","article-title":"The opioid crisis in Canada: a national perspective","volume":"38","author":"L Belzak","year":"2018","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"pone.0339643.ref018","unstructured":"Ontario Opioid Indicator Tool. 2022. [Cited 2025 March 1]. https:\/\/odprn.ca\/ontario-opioid-indicator-tool\/pain\/"},{"key":"pone.0339643.ref019","unstructured":"TPP Alberta Drug Utilization Atlas. [Cited 2025 April 1]. https:\/\/tppanalytics.ca\/"},{"issue":"12","key":"pone.0339643.ref020","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2105\/AJPH.2009.180646","article-title":"Age and gender trends in long-term opioid analgesic use for noncancer pain","volume":"100","author":"CI Campbell","year":"2010","journal-title":"Am J Public Health"},{"issue":"4","key":"pone.0339643.ref021","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YCO.0000000000000337","article-title":"Sex differences in prescription opioid use","volume":"30","author":"M Serdarevic","year":"2017","journal-title":"Curr Opin Psychiatry"},{"issue":"5","key":"pone.0339643.ref022","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jpain.2018.10.010","article-title":"Pan-Canadian estimates of chronic pain prevalence from 2000 to 2014: a repeated cross-sectional survey analysis","volume":"20","author":"MS Shupler","year":"2019","journal-title":"J Pain"},{"issue":"8","key":"pone.0339643.ref023","doi-asserted-by":"crossref","DOI":"10.51731\/cjht.2023.714","article-title":"Utilization of opioid agonist therapies in Canada","volume":"3","author":"A Mendell","year":"2023","journal-title":"cjht"},{"key":"pone.0339643.ref024","unstructured":"Health Canada. Methadone Program. 2017. [Cited 2025 April 29]. https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/exemptions\/methadone-program.html"},{"issue":"1","key":"pone.0339643.ref025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1186\/s12913-024-11281-9","article-title":"Federal opioid agonist therapy policy: interrupted time series analysis of the impact of the methadone exemption removal across eight provinces in Canada","volume":"24","author":"A Sud","year":"2024","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"pone.0339643.ref026","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1111\/add.15862","article-title":"Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study","volume":"117","author":"T Gomes","year":"2022","journal-title":"Addiction"},{"issue":"21","key":"pone.0339643.ref027","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/Naloxone vs Methadone for the treatment of opioid use disorder","volume":"332","author":"B Nosyk","year":"2024","journal-title":"JAMA"},{"key":"pone.0339643.ref028","volume-title":"NACRS Emergency Department Visits and Lengths of Stay by Province\/Territory, 2021\u20132022","author":"Canadian Institute for Health Information","year":"2022"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:22:59Z","timestamp":1768242179000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339643"}},"subtitle":[],"editor":[{"given":"Azad","family":"Haider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0339643","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}